Weiss Multi-Strategy Advisers’s Damora Therapeutics DMRA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-646	Closed	-$98K	–	723
2021 Q1	$98K	Sell	646 -1,000	-61%	-$272K	﹤0.01%	682
2020 Q4	$515K	Buy	+1,646	New	+$612K	0.01%	561

Other funds holding DMRA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's DMRA Position: Q2 2021 in Review

Weiss Multi-Strategy Advisers sold out of Damora Therapeutics (DMRA) in Q2 2021, closing a stake of 646 shares — an estimated $98K sold.

Weiss Multi-Strategy Advisers first reported a position in DMRA in Q4 2020 and held it in 2 quarters. The position peaked at $515K in Q4 2020. 26 funds tracked by Wall St. Rank hold DMRA as of Q2 2021.

Weiss Multi-Strategy Advisers reported no remaining Damora Therapeutics position as of Q2 2021 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 646 Damora Therapeutics shares in Q2 2021, an estimated $98K.
Weiss Multi-Strategy Advisers first reported a position in Damora Therapeutics in Q4 2020 and held it in 2 quarters.
Weiss Multi-Strategy Advisers's Damora Therapeutics position peaked at $515K in Q4 2020.
26 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.